5 Key Takeaways

• 1

  AI is transitioning from pilot projects to routine laboratory workflows, prompting regulators to focus on validation and governance.

• 2

  Digital tools like LIMS and ELNs enhance data integrity and efficiency, helping labs minimize human error and expedite pharmaceutical development.

• 3

  Regulatory expectations for data integrity have evolved, requiring labs to meet ALCOA++ standards throughout the entire data lifecycle.

• 4

  AI-enabled tools necessitate ongoing validation and monitoring, with a focus on input transparency and human oversight in high-risk environments.

• 5

  Compliance by design is achievable through modern digital tools that embed compliance features, but requires careful implementation and maintenance.